Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
CemiplimAb Survivorship Epidemiology
- Conditions
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT03836105
- Locations
- 🇺🇸
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
🇺🇸Harbor-UCLA/LA Biomedical Research Institute, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- ISA Pharmaceuticals
- Target Recruit Count
- 194
- Registration Number
- NCT03669718
- Locations
- 🇨🇿
Nemocnice na Bulovce, Prague, Czechia
🇲🇽Consultorio de Oncología Médica, Oaxaca, Mexico
🇮🇹ASST Spedali Civili Brescia, Department of Medical Oncology, Brescia, Italy
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT03580694
- Locations
- 🇺🇸
Regeneron Investigational Site, San Antonio, Texas, United States
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
- Conditions
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and NeckResectable Cutaneous Squamous Cell Carcinoma of the Head and NeckStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT03565783
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 690
- Registration Number
- NCT03564340
- Locations
- 🇺🇸
The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇬🇧University College London Hospitals, London, England, United Kingdom
Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT03492489
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
- Conditions
- Interventions
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03491683
- Locations
- 🇺🇸
University of Pennsylvania Health System: Penn Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Rutgers University - Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Study of Cemiplimab in Adults With Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 608
- Registration Number
- NCT03257267
- Locations
- 🇺🇸
First Health of the Carolinas Outpatient Cancer Center, Pinehurst, North Carolina, United States
🇧🇷Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
🇧🇷Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 145
- Registration Number
- NCT03233139
- Locations
- 🇯🇵
Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Osaka Medical College Hospital, Takatsuki, Osaka, Japan
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 138
- Registration Number
- NCT03132636
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Overlook Medical Center, Summit, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.